High-throughput Sequencing and Profiling of Antibody Repertoire and the Promises for Diagnostic and Therapeutic Applications

Anteneh Getachew *

Department of Biotechnology, College of Natural and Computational Sciences, Wolkite University, P.O.Box -07, Wolkite, Ethiopia.

Malaiyarasa Pandian

Department of Biotechnology, College of Natural and Computational Sciences, Wolkite University, P.O.Box -07, Wolkite, Ethiopia.

*Author to whom correspondence should be addressed.


Abstract

High-throughput DNA sequencing technologies are advancing at rapid state and transforming our indulgent about humoral immune modulation. The antibody repertoire encoded by B cells in the blood or lymphoid organs and the information obtained from high-throughput DNA sequencing of immunoglobulin genes (Ig-seq) can be applied for various disciplines. These are basically used to detect B-cell malignancies with high sensitivity and discovering specific antibodies for specific antigens. In advance, it plays significant roles in vaccine development process and it increases our understanding about autoimmunity. The broader applications of Ig-seq in clinical sets highly necessitate the development of a consistent experimental design framework that will enable the sharing and meta-analysis of sequencing data generated by many scientists. The present review attempts to give backgrounds about high-throughput antibody repertoires gene sequencing as well as the ways in which Ig-seq might be applied to characterize immune responses and identify antibodies of therapeutic, diagnostic or mechanistic relevance to autoimmune diseases.

Keywords: High-throughput, Ig-seq, sequencing, antibody repertoire, diagnostic, therapeutic.


How to Cite

Getachew, Anteneh, and Malaiyarasa Pandian. 2016. “High-Throughput Sequencing and Profiling of Antibody Repertoire and the Promises for Diagnostic and Therapeutic Applications”. Journal of Advances in Medicine and Medical Research 18 (12):1-11. https://doi.org/10.9734/BJMMR/2016/27765.

Downloads

Download data is not yet available.